All In Biotech

Drug Trial Radar · NCT05029921

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

A Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

182

Actual

Start

Dec 10, 2021

Primary completion

May 18, 2025

Study completion May 18, 2025

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.

Conditions

  • Crohn Disease

Interventions

  • UstekinumabDrug

    Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Clinical Remission at Week 8 (Co-primary Endpoint)Time frame: Week 8
  2. Percentage of Participants with Endoscopic Response at Week 16 (Co-primary Endpoint)Time frame: Week 16

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China

  • The Military General Hospital of Beijing PLA

    Beijing, China

  • The second Xiangya Hospital of Central South University

    Changsha, China

  • Changzhou No 2 Peoples Hospital

    Changzhou, China

  • West China Hospital Sichuan University

    Chengdu, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, China

  • The First Affiliated Hospital Sun Yat sen University

    Guangzhou, China

  • Guangzhou First Municipal People's Hospital

    Guangzhou, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China

  • The Second Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Anhui Province Hospital

    Hefei, China

  • Huzhou central hospital

    Huzhou, China

  • Jinhua municipal central hospital

    Jinhua, China

  • The First Affiliated Hospital of NanChang University

    Nanchang, China

  • Zhongda Hospital Southeast University

    Nanjing, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Ningbo medical center lihuili hospital

    Ningbo, China

  • Huashan Hospital Fudan University

    Shanghai, China

  • Shanghai 10th Peoples Hospital

    Shanghai, China

  • Shanghai East Hospital

    Shanghai, China

  • Shengjing Hospital Of China Medical University

    Shenyang, China

  • Peking University Shenzhen Hospital

    Shenzhen, China

  • The Second Hospital Affiliated To Suzhou University

    Suzhou, China

  • Tongji Hospital, Tongji Medical College of HUST

    Wuhan, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • Wuxi People s Hospital

    Wuxi, China

  • Yangzhou First People's Hospital

    Yangzhou, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.